Thinly traded nano cap Titan Pharmaceuticals (NASDAQ:TTNP) is up 16% premarket in reaction to European Commission approval of Sixmo-buprenorphine implant for the substitution treatment of opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine as part of overall medical, social and psychological treatment.
Italian firm Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. owns commercialization rights in Europe, certain Commonwealth of Independent States, the Middle East and North Africa.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.